Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report specifically addresses a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) under the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding internal plan transactions rather than a financial results report.
Material Changes
The filing details an increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan following a revaluation of the cash element. The transactions occurred on May 15, 2014, at a price of $55.49 per ADS. Specific increases included:
- Dr M M Slaoui: 14 ADSs
- Dr K Slaoui: 13 ADSs
- Mr W C Louv: 20 ADSs
- Mrs D P Connelly: 1 ADS
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the impact of the 401K plan revaluation on the total notional holdings of the named Directors.
- Confirm the market price of GSK ADSs on May 15, 2014, to validate the $55.49 transaction price.
- Review the full list of PDMR transactions to ensure complete disclosure compliance.